PT880363E - Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4 - Google Patents

Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4

Info

Publication number
PT880363E
PT880363E PT97907545T PT97907545T PT880363E PT 880363 E PT880363 E PT 880363E PT 97907545 T PT97907545 T PT 97907545T PT 97907545 T PT97907545 T PT 97907545T PT 880363 E PT880363 E PT 880363E
Authority
PT
Portugal
Prior art keywords
inhibitor
leucotyrene
cnting
ciclooxigenase
immunosuppressor
Prior art date
Application number
PT97907545T
Other languages
English (en)
Portuguese (pt)
Inventor
Susan A Gregory
Peter C Isakson
Gary Anderson
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of PT880363E publication Critical patent/PT880363E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT97907545T 1996-02-13 1997-02-11 Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4 PT880363E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60065596A 1996-02-13 1996-02-13

Publications (1)

Publication Number Publication Date
PT880363E true PT880363E (pt) 2002-12-31

Family

ID=24404526

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97907545T PT880363E (pt) 1996-02-13 1997-02-11 Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4

Country Status (11)

Country Link
US (3) US6407140B1 (enExample)
EP (1) EP0880363B1 (enExample)
JP (1) JP2001506574A (enExample)
AT (1) ATE223732T1 (enExample)
AU (1) AU1952597A (enExample)
CA (1) CA2246336A1 (enExample)
DE (1) DE69715382T2 (enExample)
DK (1) DK0880363T3 (enExample)
ES (1) ES2183140T3 (enExample)
PT (1) PT880363E (enExample)
WO (1) WO1997029774A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029776A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
DE69715382T2 (de) * 1996-02-13 2003-04-30 G.D. Searle & Co., Chicago Arzneimittelkombinationen mit immunosuppressiven wirkungen welche cyclooxygenase-2 inhibitoren und leukotrien lta4 hydrase-inhibitoren enthalten
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
PT1303265E (pt) * 2000-07-20 2007-10-09 Lauras As ''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida''
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
MXPA04003451A (es) 2001-10-09 2005-02-17 Dimensional Pharm Inc Difeniloxazoles substituidos, la sintesis de los mismos y el uso de los mismo como detectores fluorescencia.
AU2003263043A1 (en) * 2002-08-28 2004-03-19 Sangstat Medical Corporation Methods and compostions for immune tolerance
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
GT200600158A (es) * 2005-04-22 2006-11-28 Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
AT502258B1 (de) * 2005-07-22 2007-09-15 Univ Wien Cox-i-inhibitorverbindungen
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US7737145B2 (en) * 2005-12-29 2010-06-15 Estrellita Pharmaceuticals, Llc Diamine derivatives as inhibitors of leukotriene A4 hydrolase
TW200932236A (en) * 2007-10-31 2009-08-01 Janssen Pharmaceutica Nv Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase
RS52712B (sr) 2008-04-11 2013-08-30 Janssen Pharmaceutica N.V. Tiazolopiridin-2-iloksi-fenil i tiazolopirazin-2-iloksi-fenil amini kao modulatori leukotrien a4 hidrolaze
MX2011012190A (es) 2009-05-14 2011-12-08 Janssen Pharmaceutica Nv Compuestos con dos porciones de heteroarilo biciclico fusionado como moduladores de la leucotrieno a4 hidrolasa.
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CA2905340C (en) 2013-03-12 2022-05-31 Celtaxsys, Inc. Low dose oral formulations of acebilustat
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
JP6534650B2 (ja) 2013-03-14 2019-06-26 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
EP2968265A4 (en) 2013-03-14 2016-12-28 Celtaxsys Inc INHIBITORS OF THE LEUKOTRIEN A4 HYDROLASE
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
SI3730487T1 (sl) 2016-06-13 2022-08-31 Gilead Sciences, Inc. Azetidinski derivati kot modulatorji FXR (NR1H4)
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
US11225473B2 (en) 2019-01-15 2022-01-18 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
EP3927683A1 (en) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Solid forms of fxr agonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196839A (ja) 1983-04-21 1984-11-08 Sankyo Co Ltd フエニル酢酸誘導体
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5242940A (en) 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
ATE109970T1 (de) 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US5234950A (en) 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
GB8927287D0 (en) 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
US5220059A (en) 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
WO1992001682A1 (en) 1990-07-25 1992-02-06 Abbott Laboratories Acetylene derivatives having lipoxygenase inhibitory activity
IE913655A1 (en) 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
JPH06505239A (ja) 1991-01-31 1994-06-16 ワーナー−ランバート・コンパニー 抗炎症剤として有用な４，６−ジ−第三ブチル−５−ヒドロキシ−１，３−ピリミジンの置換されたヘテロアリール類似体
GB9215921D0 (en) 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
US5354865A (en) 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
US5288751A (en) 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
CA2152792C (en) 1993-01-15 2000-02-15 Stephen R. Bertenshaw Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6718494A (en) 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5298521A (en) 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
ATE233245T1 (de) 1993-11-30 2003-03-15 Searle & Co Substituierte pyrazolyl-benzolsulfonamide und ihre verwendung als cyclooxygenaseii inhibitoren
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
CA2224517A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
DE69715382T2 (de) * 1996-02-13 2003-04-30 G.D. Searle & Co., Chicago Arzneimittelkombinationen mit immunosuppressiven wirkungen welche cyclooxygenase-2 inhibitoren und leukotrien lta4 hydrase-inhibitoren enthalten
PT880362E (pt) * 1996-02-13 2005-10-31 Searle & Co Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4

Also Published As

Publication number Publication date
US6407140B1 (en) 2002-06-18
DE69715382D1 (de) 2002-10-17
ATE223732T1 (de) 2002-09-15
US20030004191A1 (en) 2003-01-02
US20050043355A1 (en) 2005-02-24
JP2001506574A (ja) 2001-05-22
AU1952597A (en) 1997-09-02
EP0880363A1 (en) 1998-12-02
DK0880363T3 (da) 2003-01-20
ES2183140T3 (es) 2003-03-16
WO1997029774A1 (en) 1997-08-21
CA2246336A1 (en) 1997-08-21
DE69715382T2 (de) 2003-04-30
EP0880363B1 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
PT880363E (pt) Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4
NO942351D0 (enExample)
MX9805810A (es) Agentes anticoagulantes, utiles en el tratamiento de trombosis.
DE59710893D1 (de) Kosmetische oder pharmazeutische zubereitungen mit vermindertem klebrigkeitsgefühl
ATE395418T1 (de) Alpha(1,3)galactosyltransferase-negatives schwein
ID22042A (id) Benzonaftiridin sebagai pengobatan cabang tenggorokan
FI970747A0 (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
TR200100774T2 (tr) Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı aterosklerozis tedavi yöntemi
ATE224208T1 (de) Wasserlöslicher film
BR9707353A (pt) Preparações que promovem o crescimento de unhas
DK0837935T3 (da) Den 3'-ikke-translaterede region af det humane prohibitin-gen
PT766557E (pt) Composicoes de aplicacao topica compreendendo n-acetil-cisteina
DE59510667D1 (de) Pyridylthioverbindungen zur bekämpfung von helicobacter-bakterien
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
EP0970612A4 (en) INHIBITORS OF ALGAE GROWTH AND MICROBIAL PROPAGATION AND THEIR USE
AU3851095A (en) Assay
DK0563256T3 (da) Anvendelse af værtscelle-phospholipider til inhibering af bakteriekolonisering
DE69632407D1 (de) Antikörper gegen l-selectin zur vorbeugung von multiplem organversagen und akuter organschädigung
IL124733A0 (en) Composition for organ cryopreservation and treatment of viral and bacterial infections
ATE218877T1 (de) Bowman-birk-inhibitorzusammensetzungen zur behandlung von entzündungskrankheiten
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
AU116665S (en) Pen
BR9106762A (pt) Derivado de aldc e uso do mesmo